Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-174

I agree Platinum. The quarterly will be useless as an indicator going forward. I expect it to lumpy and not a true reflection of how the future will look. While TAVR is a priority we need to remember we retained the IP from which CardioCel and VascuCel was derived.

There is much scope for other products and devices going forward using Adapt treated tissue that can be licenced or sold. The LeMaitre deal has shown that, we can do a good deal, even with capital restraints, the competition recognise our “next generation tissue”, the large peer reviewed studies are out there and now a Nasdaq listed company has told all their shareholders and the industry about little Admedus. A little Admedus that still retains the IP that makes the difference to the products they purchased.

it’s easy to think we have hitched our wagon to TAVR or moved out of what we know but we know tissue and our IP is and always has been what is valuable about our company.